BLASTICIDIN_S


Synonyms	Blasticidin S
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	CXNPLSGKWMLZPZ-ZNIXKSQXSA-N
Smiles	CN(CC[C@H](N)CC(=O)N[C@H]1C=C[C@@H](O[C@@H]1C(=O)O)N2C=CC(=NC2=O)N)C(=N)N
InChI	InChI=1S/C17H26N8O5/c1-24(16(20)21)6-4-9(18)8-12(26)22-10-2-3-13(30-14(10)15(27)28)25-7-5-11(19)23-17(25)29/h2-3,5,7,9-10,13-14H,4,6,8,18H2,1H3,(H3,20,21)(H,22,26)(H,27,28)(H2,19,23,29)/t9-,10-,13+,14-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C17H26N8O5
Molecular Weight	422.44
AlogP	-5.42
Hydrogen Bond Acceptor	9.0
Hydrogen Bond Donor	6.0
Number of Rotational Bond	9.0
Polar Surface Area	213.45
Molecular species	ZWITTERION
Aromatic Rings	0.0
Heavy Atoms	30.0

Assay Description	Organism	Bioactivity
Fungicidal activity against Magnaporthe grisea P-2 assessed as inhibition of appressorium formation at 10 ug/ml	Magnaporthe grisea	None
Fungicidal activity against Magnaporthe grisea P-2 assessed as inhibition of appressorium formation at 1 ug/ml	Magnaporthe grisea	25.2 %
Fungicidal activity against Magnaporthe grisea P-2 assessed as inhibition of spore germination at 10 ug/ml	Magnaporthe grisea	100.0 %
Fungicidal activity against Magnaporthe grisea P-2 assessed as inhibition of spore germination at 1 ug/ml	Magnaporthe grisea	76.6 %
Fungicidal activity against Magnaporthe grisea P-2 in rice plant assessed as systemic effect of rice blast disease measured as percentage of lesion area in third leaf at 100 ug/ml	Magnaporthe grisea	None
Fungicidal activity against Magnaporthe grisea P-2 in rice plant assessed as curative effect of rice blast disease measured as percentage of lesion area in third leaf at 100 ug/ml	Magnaporthe grisea	94.3 %
Antifungal activity against Fusarium avenaceum VIAM MA1512 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	Fusarium avenaceum	25.0 ug.mL-1	Antifungal activity against Fusarium avenaceum VIAM MA1512 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	Fusarium avenaceum	7.0 ug ml-1	Antifungal activity against Fusarium avenaceum VIAM MA1512 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	Fusarium avenaceum	0.4 ug.mL-1
Antifungal activity against Alternaria citri CBS 192.81; VIAM MA1628 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	Alternaria citri	50.0 ug.mL-1	Antifungal activity against Alternaria citri CBS 192.81; VIAM MA1628 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	Alternaria citri	53.0 ug ml-1	Antifungal activity against Alternaria citri CBS 192.81; VIAM MA1628 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	Alternaria citri	6.0 ug.mL-1
Antifungal activity against Magnaporthe grisea VIAM MA1627 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	Magnaporthe grisea	200.0 ug.mL-1	Antifungal activity against Magnaporthe grisea VIAM MA1627 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	Magnaporthe grisea	200.0 ug ml-1	Antifungal activity against Magnaporthe grisea VIAM MA1627 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	Magnaporthe grisea	13.0 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL476894
PDB	BLS
PubChem	170012
SureChEMBL	SCHEMBL73841

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).